AorTech International PLC Result of GM and TVR (8036Q)
08 June 2018 - 9:02PM
UK Regulatory
TIDMAOR
RNS Number : 8036Q
AorTech International PLC
08 June 2018
8 June 2018
AorTech International plc
("AorTech" or the "Company")
Result of General Meeting
and
Total Voting Rights
AorTech International plc (AIM: AOR), the biomaterials and
medical device IP company, announces that all resolutions put to
Shareholders at the General Meeting held earlier today were duly
passed.
Application has therefore been made for, in aggregate, 9,128,913
new Ordinary Shares to be admitted to trading on AIM comprising
5,740,267 Placing Shares, 1,260,004 Subscription Shares, 461,333
Consideration Shares and 1,667,309 Open Offer Shares. Admission is
expected to occur at 8.00 am on 11 June 2018.
Following Admission, the Company will have 14,686,608 Ordinary
Shares in issue admitted to trading on AIM. This figure may be used
by Shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, the Company under the
Financial Conduct Authority's Disclosure Guidance and Transparency
Rules.
This announcement should be read in conjunction with the full
text of the Circular which was posted to Shareholders on 22 May
2018, copies of which are available on the Company's website at
www.aortech.net. Capitalised terms in this announcement have the
same meaning as given in the Circular.
This announcement includes inside information as defined in
Article 7 of the Market Abuse Regulation No. 596/2014 and is
disclosed in accordance with the Company's obligations under
Article 17 of those Regulations.
For further information contact:
AorTech International plc Tel: +44 (0)7730 718296
Bill Brown, Chairman
Stockdale Securities Limited Tel: +44 20 7601 6100
Tom Griffiths/David Coaten
About AorTech:
AorTech has developed biostable, implantable polymers, including
Elast-Eon(TM) and ECSil(TM) the world's leading long-term
implantable co-polymers, now manufactured on their behalf by
Biomerics LLC in Utah, USA. With several million implants and seven
years of successful clinical use, AorTech polymers are being
developed and used in cardiology and urological applications,
including pacing leads, cardiac cannulae, stents and neuro
stimulation devices. Devices manufactured from AorTech polymers
have numerous US FDA PMA approvals, 510ks, CE Marks, Australian TGA
and Japanese Ministry of Health approvals.
Elast-Eon(TM) and ECSil(TM)'s biostability is comparable to
silicone while exhibiting excellent mechanical, blood contacting
and flex-fatigue properties. These polymers can be processed using
conventional thermoplastic extrusion and moulding techniques. A
range of materials in a variety of application-specific
formulations for use in medical devices and components are
available.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCKMGGVGRLGRZM
(END) Dow Jones Newswires
June 08, 2018 07:02 ET (11:02 GMT)
Rua Life Sciences (LSE:RUA)
Historical Stock Chart
From Apr 2024 to May 2024
Rua Life Sciences (LSE:RUA)
Historical Stock Chart
From May 2023 to May 2024